Morgan Stanley Adc Therapeutics Sa Transaction History
Morgan Stanley
- $1.59 Trillion
- Q3 2025
A detailed history of Morgan Stanley transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Morgan Stanley holds 3,669,067 shares of ADCT stock, worth $14.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,669,067
Previous 3,045,573
20.47%
Holding current value
$14.5 Million
Previous $8.16 Million
79.81%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding ADCT
# of Institutions
107Shares Held
67.3MCall Options Held
39.8KPut Options Held
68.4K-
Redmile Group, LLC San Francisco, CA15.7MShares$62 Million6.9% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.14MShares$32.2 Million0.06% of portfolio
-
Prosight Management, LP Dallas, TX7.47MShares$29.6 Million7.9% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$23.4 Million0.81% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$14.1 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $307M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...